TTRXHealthcare · Biotechnology

TTRX Stock Forecast: Turn Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$9.46

−0.84% on the day

The 1 Wall Street analysts covering Turn Therapeutics, Inc. hold a median 12-month price target of $26 — +174.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$287.3M

Ticker Nerd rank

17 / 100

Median analyst target

$26

Analysts covering

Total return, dividends reinvested

−1.1%

−7.1%

YTD

+140.1%

From high

−10.2%

From low

+249.1%

$11

Range since 8 Oct 2025, adjusted closes · the dot is the last close

Ticker Nerd rank

TTRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Turn Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value

Size

Accruals

Revisions

Quality

Growth

Momentum

Issuance

Volatility

Value (80): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TTRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TTRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 8 Oct 2025Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $26Median $26High $26

The green dot is the last close — the median target sits +174.8% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
24 Mar 2026	D. Boral Capital	Maintains	Buy	$8.00
24 Mar 2026	D. Boral Capital	Maintains	Buy	—
20 Jan 2026	D. Boral Capital	Maintains	Buy	—
29 Dec 2025	D. Boral Capital	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TTRX appears on the weeks it earns a place.

Estimates

TTRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Turn Therapeutics, Inc. (TTRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −79.1×
Price / sales: —
Price / book: 46.1×
EV / EBITDA: −32.6×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −686.3%
Return on assets: −50.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TTRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
TTRXTurn Therapeutics, Inc.	$287.3M	17
ELDNEledon Pharmaceuticals, Inc.	$280.4M	34
CAMPCAMP4 Therapeutics Corp.	$281.1M	59
SRZNSurrozen, Inc.	$275.6M	77
ALXOALX Oncology Holdings, Inc.	$282.1M	63
FATEFate Therapeutics, Inc.	$270.9M	93
ACIUAC Immune SA	$286.9M	34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Turn Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TTRX news & analysis

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

Business Wire · 20 Aug 2026positive

Turn Therapeutics announced the publication of new peer-reviewed research in the journal Life providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several key inflammatory signals and drivers of itch associated with inflammatory skin disease.

Why it matters — The peer-reviewed in-vivo findings add scientific validation for GX-03, Turn Therapeutics' lead investigational therapy for inflammatory skin conditions.

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Business Wire · 12 Aug 2026positive

Turn Therapeutics provided corporate updates and reported financial results for the three and six months ended June 30, 2026. The company's review of interim GX-03 Phase 2 data indicated activity across a broader range of conditions, with management describing the second quarter as one of the most productive in its history.

Why it matters — A Turn Therapeutics watcher would care because the interim GX-03 Phase 2 data update and quarterly financial report provide an early look at the clinical progress and financial position of its lead skin-disease therapy candidate.

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

Business Wire · 28 July 2026positive

Turn Therapeutics announced that CEO Bradley Burnam and members of the management team will ring the Nasdaq Closing Bell on August 10, 2026, at Nasdaq's invitation to mark the company's progress to date.

Why it matters — The Nasdaq's invitation for Turn Therapeutics to ring the closing bell signals recognition of the company's achievements and milestones as a publicly traded clinical-stage biotechnology firm.

FAQ

Frequently asked questions about TTRX stock

What is the TTRX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Turn Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $26 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TTRX stock a buy right now?

Of the 1 analysts covering Turn Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Turn Therapeutics, Inc. 17 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TTRX?

As at 22 Aug 2026, Turn Therapeutics, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (80 of 100).

Will TTRX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +174.8% from the last close, and Ticker Nerd's factor model ranks Turn Therapeutics, Inc. 17 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TTRX stock forecast for 2030?

No analyst covering Turn Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TTRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $26 over the next 12 months.

What does Turn Therapeutics, Inc. do?

Turn Therapeutics Inc. is a biotechnology and pharmaceuticals company dedicated to developing innovative drugs and medical devices for dermatological, wound care, and infectious disease management.

What is the latest news on TTRX?

The most recent item we track (Business Wire, 20 Aug 2026): "Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch". Turn Therapeutics announced the publication of new peer-reviewed research in the journal Life providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several key inflammatory signals and drivers of itch associated with inflammatory skin disease.

Company

About Turn Therapeutics, Inc.

Turn Therapeutics Inc. is a biotechnology and pharmaceuticals company dedicated to developing innovative drugs and medical devices for dermatological, wound care, and infectious disease management. Central to its approach is the proprietary PermaFusion drug delivery platform, which enables the stable suspension of water-soluble active pharmaceutical ingredients within oil-based carriers, enhancing bioavailability and reducing the risk of adverse effects tied to lower active ingredient dosages. Founded in 2015 and headquartered in Westlake Village, California, the company focuses primarily on diseases of the skin, nails, and eyes, with significant research and clinical programs addressing moderate to severe eczema and onychomycosis (nail fungus). Turn Therapeutics' technologies, including its flagship Hexagen formula, have achieved multiple FDA medical device clearances for advanced wound and dermatitis care, substantiating their safety and efficacy. The company’s mission centers on advancing patient-centric therapies that minimize invasiveness and antibiotic resistance, respond to unmet medical needs, and continuously redefine standards of care in the healthcare and biotechnology sectors.

CEO Mr. Bradley E. Burnam · 2 employees · United States · https://turntherapeutics.com